Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community

22 June 2018

Medicines for Europe is committed to bringing accessible, high quality […]

Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

14 June 2018

The joint 24th Medicines for Europe and 21st IGBA Annual […]

IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly

7 June 2018

Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe

28 May 2018

Medicines for Europe commends the European Commission for proposing an […]

EU Semester Country Specific Recommendations: Improve patient access to medicine and ensure healthcare sustainability

24 May 2018

The European Semester Country Specific Recommendations show that healthcare systems […]

Biosimilar Medicines: essential for sustainable access to medicines

26 April 2018

Opening the 16th Biosimilar Medicines Conference, Keith Ridge, Chief Pharmaceutical […]

SPC manufacturing waiver, Competition policy, Brexit, pharma incentives European Patent Office take centre stage at 14^th Legal Affairs Conference

25 April 2018

Key authorities, lawyers and industry leaders discussed today in London […]

Joint Declaration on Pharmaceuticals in the Environment

10 April 2018

We, the signatories of this declaration, recognise and understand the […]

Statement in response to the EU Council ratifying the Brexit transition deal

23 March 2018

Today’s agreement on a transition period is welcome news for […]

European health community issues key questions Article 50 negotiations must answer for patients and public health

8 March 2018

The European Health Community has warned that time is running […]